Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027
Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGOAdditionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027
Supernus got special protection for a rare disease drug for seven years. They are also working on a backup supplier to keep it available.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.